Tag Archives: Chantrix

Accelerated Approvals Could Raise Risks for Patients

By Erik Greb. FDA approved 35 innovative drugs in fiscal 2011, including treatments for hepatitis C, prostate cancer, Hodgkin’s lymphoma, and lupus. This number of approvals is among the highest in the past 10 years, and it reflects the agency’s efforts to hasten patients’ access to new drugs. In the past two years, the agency’s […]
Posted in Guest Blog, Regulatory, Safety | Also tagged , , , | Leave a comment
  • Categories

  • Meta